Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | PGRMC1 | O00264 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | PCYT1A | P49585 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15191642 | 0.91 | BRAF (0.36) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL574919 | 0.91 | BRAF (0.35) | BRAFMAPK14HCRTR1HCRTR2 | |
| SCHEMBL574846 | 0.89 | BRAF (0.33) | BRAFMAPK14MAPK13CSNK1DCSNK1E | |
| SCHEMBL15198328 | 0.87 | BRAF (0.32) | BRAF | |
| SCHEMBL574889 | 0.87 | MEN1 (0.35) | BRAFMAPK14MAPK13CSNK1DCSNK1E | |
| SCHEMBL15192209 | 0.87 | PDE10A (0.36) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL15191841 | 0.87 | BRAF (0.37) | BRAFMAPK14MAPK13CSNK1DCSNK1E | |
| SCHEMBL574504 | 0.86 | EGFR (0.37) | BRAFMAPK14CSNK1DCSNK1ERIPK2 | |
| SCHEMBL15191686 | 0.86 | ROS1 (0.33) | HCRTR1HCRTR2 | |
| SCHEMBL574887 | 0.84 | BRAF (0.49) | BRAFMAPK14PGRMC1RIPK2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| EP-2601185-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016993-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | CDK2, CDK1, CDK4 | BRAF 8/4885MAPK14 152/4885MAPK13 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.